A Phase 2 interventional study of 5-ALA (Gliolan) in Brain Tumor, sponsored by University College, London. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-03-27.
Sponsored by University College, London · Phase 2, Interventional, and Other
The aim of the study is to examine the safety and feasibility of using 5-ALA in children who have MRI scans showing an aggressive looking brain tumour. It will also study if 5-ALA can help the surgeon achieve maximal tumour removal and discriminate between normal brain tissue and tumour.
Patients will be between 3-18 years (inclusive) and all patients will receive 5-ALA 3-6 hours prior to resection surgery.
1,960 studies on the registry are indexed under Brain Neoplasms; 516 are open to participants now.
This study's planned enrollment of 80 is above the median of 40 across 1,458 interventional studies indexed under Brain Neoplasms.
Browse Brain Neoplasms studies →University College, London is the lead sponsor of 632 studies on the registry; 145 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adequate liver and kidney function
Normal Coagulation profile
o Prothombin Time, Activated Partial Prothombin Time and Thrombin Time all within normal limits
Exclusion Criteria:
This is a single-arm study with two cohorts
Drug: 5-ALA (Gliolan)
Gliolan 30 ml/mg powder for oral solution, Single dose 3-6 hours prior to surgery
Cohort 1: Complete resection rate and fluorescence rate of supratentorial instrinsic high grade brain tumours. Cohort 2: Fluorescence rate of infratentorial tumours.
Timeframe between informed consent and surgery
Time frame: Two weeks
Plan to share: No — Following data protection guidance
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University College, London